FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890128092> ?p ?o ?g. }

• W2890128092 endingPage "590" @default.
• W2890128092 startingPage "568" @default.
• W2890128092 abstract "Sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI), is the first medication to demonstrate a mortality benefit in patients with chronic heart failure and reduced ejection fraction (HFrEF) since the early 2000s. Sacubitril/valsartan simultaneously suppresses renin-angiotensin-aldosterone system activation through blockade of angiotensin II type 1 receptors and enhances the activity of vasoactive peptides including natriuretic peptides, through inhibition of neprilysin, the enzyme responsible for their degradation. In the landmark PARADIGM-HF trial, patients with HFrEF treated with sacubitril/valsartan had a 20% reduction in the primary composite endpoint of cardiovascular death or heart failure hospitalization, a 20% lower risk of cardiovascular death, a 21% to 20% lower risk of a first heart failure hospitalization, and a 16% to 20% lower risk of death from any cause, compared with subjects allocated to enalapril (all p<0.001).Following the trial, new international guidelines endorsed sacubitril/valsartan as a class I recommendation for the management of patients with HFrEF who remain symptomatic despite optimal medical management. In Italy, sacubitril/valsartan is reimbursed by the National Health Service since March 2017 within criteria set by the Italian Medicines Agency subject to patient inclusion in a dedicated monitoring registry. Although numerous post-hoc analyses of the original trial suggested that the benefits of this innovative medication may extend across a variety of subgroups, many questions do not yet have an evidence-based answer.In this position paper, we discuss the current role of sacubitril/valsartan in the management of chronic HFrEF, treatment eligibility and the modulating role of patients' characteristics. Moreover, we address concerns elicited by the PARADIGM-HF study and shortcomings of this novel drug, to clarify the place of this new therapy in the context of global care of heart failure in Italy. Our aim is to provide clinical cardiologists with a concise and practical guidance on when and how to use sacubitril/valsartan, to assist clinicians in closing the gap between scientific innovation and real-world experience." @default.
• W2890128092 created "2018-09-27" @default.
• W2890128092 creator A5012000957 @default.
• W2890128092 creator A5013069712 @default.
• W2890128092 creator A5018004237 @default.
• W2890128092 creator A5018381736 @default.
• W2890128092 creator A5032174472 @default.
• W2890128092 creator A5039368555 @default.
• W2890128092 creator A5053905470 @default.
• W2890128092 creator A5056089291 @default.
• W2890128092 creator A5058318945 @default.
• W2890128092 creator A5060241741 @default.
• W2890128092 creator A5061010242 @default.
• W2890128092 creator A5061833973 @default.
• W2890128092 creator A5065053773 @default.
• W2890128092 creator A5068319384 @default.
• W2890128092 creator A5079848466 @default.
• W2890128092 creator A5081154400 @default.
• W2890128092 date "2018-10-01" @default.
• W2890128092 modified "2023-09-29" @default.
• W2890128092 title "[ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure]." @default.
• W2890128092 doi "https://doi.org/10.1714/2978.29843" @default.
• W2890128092 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30281045" @default.
• W2890128092 hasPublicationYear "2018" @default.
• W2890128092 type Work @default.
• W2890128092 sameAs 2890128092 @default.
• W2890128092 citedByCount "1" @default.
• W2890128092 countsByYear W28901280922021 @default.
• W2890128092 crossrefType "journal-article" @default.
• W2890128092 hasAuthorship W2890128092A5012000957 @default.
• W2890128092 hasAuthorship W2890128092A5013069712 @default.
• W2890128092 hasAuthorship W2890128092A5018004237 @default.
• W2890128092 hasAuthorship W2890128092A5018381736 @default.
• W2890128092 hasAuthorship W2890128092A5032174472 @default.
• W2890128092 hasAuthorship W2890128092A5039368555 @default.
• W2890128092 hasAuthorship W2890128092A5053905470 @default.
• W2890128092 hasAuthorship W2890128092A5056089291 @default.
• W2890128092 hasAuthorship W2890128092A5058318945 @default.
• W2890128092 hasAuthorship W2890128092A5060241741 @default.
• W2890128092 hasAuthorship W2890128092A5061010242 @default.
• W2890128092 hasAuthorship W2890128092A5061833973 @default.
• W2890128092 hasAuthorship W2890128092A5065053773 @default.
• W2890128092 hasAuthorship W2890128092A5068319384 @default.
• W2890128092 hasAuthorship W2890128092A5079848466 @default.
• W2890128092 hasAuthorship W2890128092A5081154400 @default.
• W2890128092 hasConcept C104849204 @default.
• W2890128092 hasConcept C126322002 @default.
• W2890128092 hasConcept C164705383 @default.
• W2890128092 hasConcept C177713679 @default.
• W2890128092 hasConcept C203092338 @default.
• W2890128092 hasConcept C27016395 @default.
• W2890128092 hasConcept C2775940317 @default.
• W2890128092 hasConcept C2775999527 @default.
• W2890128092 hasConcept C2776754050 @default.
• W2890128092 hasConcept C2777387769 @default.
• W2890128092 hasConcept C2778198053 @default.
• W2890128092 hasConcept C2908929049 @default.
• W2890128092 hasConcept C535046627 @default.
• W2890128092 hasConcept C71924100 @default.
• W2890128092 hasConcept C78085059 @default.
• W2890128092 hasConcept C84393581 @default.
• W2890128092 hasConceptScore W2890128092C104849204 @default.
• W2890128092 hasConceptScore W2890128092C126322002 @default.
• W2890128092 hasConceptScore W2890128092C164705383 @default.
• W2890128092 hasConceptScore W2890128092C177713679 @default.
• W2890128092 hasConceptScore W2890128092C203092338 @default.
• W2890128092 hasConceptScore W2890128092C27016395 @default.
• W2890128092 hasConceptScore W2890128092C2775940317 @default.
• W2890128092 hasConceptScore W2890128092C2775999527 @default.
• W2890128092 hasConceptScore W2890128092C2776754050 @default.
• W2890128092 hasConceptScore W2890128092C2777387769 @default.
• W2890128092 hasConceptScore W2890128092C2778198053 @default.
• W2890128092 hasConceptScore W2890128092C2908929049 @default.
• W2890128092 hasConceptScore W2890128092C535046627 @default.
• W2890128092 hasConceptScore W2890128092C71924100 @default.
• W2890128092 hasConceptScore W2890128092C78085059 @default.
• W2890128092 hasConceptScore W2890128092C84393581 @default.
• W2890128092 hasIssue "10" @default.
• W2890128092 hasLocation W28901280921 @default.
• W2890128092 hasOpenAccess W2890128092 @default.
• W2890128092 hasPrimaryLocation W28901280921 @default.
• W2890128092 hasRelatedWork W118692828 @default.
• W2890128092 hasRelatedWork W1992098220 @default.
• W2890128092 hasRelatedWork W2130271234 @default.
• W2890128092 hasRelatedWork W2337127286 @default.
• W2890128092 hasRelatedWork W2345053918 @default.
• W2890128092 hasRelatedWork W2470465590 @default.
• W2890128092 hasRelatedWork W2507866328 @default.
• W2890128092 hasRelatedWork W2624092862 @default.
• W2890128092 hasRelatedWork W2757647121 @default.
• W2890128092 hasRelatedWork W2763343438 @default.
• W2890128092 hasRelatedWork W2791543777 @default.
• W2890128092 hasRelatedWork W2805439296 @default.
• W2890128092 hasRelatedWork W2810662961 @default.
• W2890128092 hasRelatedWork W2969849159 @default.
• W2890128092 hasRelatedWork W2973195048 @default.
• W2890128092 hasRelatedWork W2989920874 @default.
• W2890128092 hasRelatedWork W2994733800 @default.

• next